Aralez Pharmaceuticals Inc. (ARLZ) Insider Sells $10,267.60 in Stock
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) insider Eric Trachtenberg sold 7,720 shares of the firm’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $1.33, for a total transaction of $10,267.60. Following the completion of the transaction, the insider now directly owns 201,564 shares of the company’s stock, valued at approximately $268,080.12. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Aralez Pharmaceuticals Inc. (ARLZ) traded down 0.75% during trading on Friday, reaching $1.32. 538,110 shares of the company were exchanged. The firm has a 50-day moving average of $1.34 and a 200-day moving average of $2.98. The firm’s market cap is $86.92 million. Aralez Pharmaceuticals Inc. has a 52-week low of $1.09 and a 52-week high of $6.80.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings data on Tuesday, May 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by $0.02. Aralez Pharmaceuticals had a negative return on equity of 66.74% and a negative net margin of 133.92%. The company had revenue of $26 million for the quarter, compared to the consensus estimate of $20.23 million. During the same period in the prior year, the company earned ($0.73) EPS. The firm’s revenue was up 221.0% on a year-over-year basis. On average, equities analysts forecast that Aralez Pharmaceuticals Inc. will post ($1.56) EPS for the current year.
Large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. increased its stake in shares of Aralez Pharmaceuticals by 0.3% in the first quarter. Goldman Sachs Group Inc. now owns 121,494 shares of the company’s stock valued at $260,000 after buying an additional 354 shares in the last quarter. FNY Managed Accounts LLC increased its stake in shares of Aralez Pharmaceuticals by 4.2% in the first quarter. FNY Managed Accounts LLC now owns 77,119 shares of the company’s stock valued at $165,000 after buying an additional 3,136 shares in the last quarter. Broadfin Capital LLC increased its stake in shares of Aralez Pharmaceuticals by 8.3% in the first quarter. Broadfin Capital LLC now owns 5,191,590 shares of the company’s stock valued at $11,110,000 after buying an additional 400,000 shares in the last quarter. KCG Holdings Inc. bought a new stake in shares of Aralez Pharmaceuticals during the first quarter valued at about $310,000. Finally, Elk Creek Partners LLC increased its stake in shares of Aralez Pharmaceuticals by 13.3% in the first quarter. Elk Creek Partners LLC now owns 2,488,475 shares of the company’s stock valued at $5,325,000 after buying an additional 292,420 shares in the last quarter. 35.64% of the stock is owned by institutional investors.
ARLZ has been the subject of a number of recent analyst reports. Chardan Capital decreased their price objective on shares of Aralez Pharmaceuticals from $10.00 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, March 15th. Bloom Burton raised shares of Aralez Pharmaceuticals from an “accumulate” rating to a “buy” rating in a research note on Monday, April 10th. Finally, ValuEngine lowered shares of Aralez Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.